T cell boosting therapy expands into oncology

By Maggie Lynch

- Last updated on GMT

(Image: Getty/Design Cells)
(Image: Getty/Design Cells)

Related tags Oncology Immuno-oncology T cell receptor T cells

US FDA grants orphan drug designation for Hyleukin-7, an immuno-oncology agent that boosts T cell production and functionality, for the treatment of ICL.

NeoImmuneTech’s Hyleukin-7 (rhIL-7-hyFc, NT-I7) was granted an orphan drug designation by the US Food and Drug Administration (FDA) for the treatment of idiopathic CD4+ lymphocytopenia (ICL). The drug candidate also received an orphan drug designation from the European Medicines Agency in 2017.

Additionally, the T cell amplifier is being investigated for the potential treatment of cancer, in combination with current oncology therapies.

ICL is a rare disease that causes patients without HIV or any immunodeficiency to have persistently low CD4+ T lymphocyte counts. Individuals with ICL are at a high risk for developing certain types of cancer and recurrent infections.

According to the company, Hyleukin-7 is designed to increase a patient’s T cells and is predicted to broaden T cell receptor diversity, which could bolster T cell responses.

The drug candidate amplifies T cell immunity in the treatment of patients with cancer and ICL, therefore providing treatment opportunities for immuno-oncology combination strategies, potentially alongside anti-PD-(L)1 agents or chemotherapy.

The orphan drug designation comes after a Phase I trial in healthy participants and multiple ongoing dose-escalation trials in cancer patients showed a well-tolerated safety profile and dose-dependent increases of CD4+ and CD8+ T lymphocyte counts.

According to NeoImmuneTech, Hyleukin-7 has the potential to amplify and prolong anti-tumor activity, which could extend survival for cancer patients. It is being studied in clinical trials for solid tumors and hematologic malignancies, in addition to its indication for ICL.

Related news

Follow us

Webinars

Headlines